Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1
- 1 September 1995
- journal article
- Published by Elsevier in The Lancet
- Vol. 346 (8978) , 805-806
- https://doi.org/10.1016/s0140-6736(95)91621-0
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxisThe Lancet, 1995
- Donor T Cells to Treat EBV-Associated LymphomaNew England Journal of Medicine, 1994
- Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host diseaseBlood, 1994
- Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptorBlood, 1994
- Cyclosporine, Methotrexate, and Prednisone Compared with Cyclosporine and Prednisone for Prophylaxis of Acute Graft-versus-Host DiseaseNew England Journal of Medicine, 1993
- Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host diseaseBlood, 1992
- Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid- resistant acute graft-versus-host diseaseBlood, 1990
- DEPLETION OF T LYMPHOCYTES IN DONOR MARROW PREVENTS SIGNIFICANT GRAFT-VERSUS-HOST DISEASE IN MATCHED ALLOGENEIC LEUKAEMIC MARROW TRANSPLANT RECIPIENTSThe Lancet, 1984
- REVERSAL OF TRANSPLANT REJECTION BY MONOCLONAL ANTIBLAST ANTIBODYThe Lancet, 1983
- Monoclonal and Heteroantibody Reacting with Different Antigens Common to Human Blast Cells and MonocytesHybridoma, 1982